WBL Peking University Biotech

WBL Peking University Biotech is a Chinese biopharmaceutical company specializing in the research, development, and manufacturing of natural medicines and health products. The company is most notably recognized for developing Xuezhikang, a proprietary red yeast rice extract used for the treatment of hyperlipidemia and the prevention of cardiovascular diseases. Originally established as a high-tech enterprise linked to Peking University, the company has successfully commercialized traditional Chinese medicine-derived products using modern pharmacological standards. In 2013, the company was acquired by Luye Pharma Group, which has since integrated WBL's cardiovascular portfolio into its global commercial strategy. WBL Peking University Biotech continues to operate as a key subsidiary focused on lipid-lowering therapies and natural product innovation.